Back to search

Cornell University

DESIGN AND EVALUATION OF MECHANISM-BASED SIRT2 INHIBITORS WITH ENHANCED ANTICANCER POTENCY

Abstract

dc:description.abstract

SIRT2 regulates various biological pathways through lysine deacetylation and de-fatty acylation, thereby promoting tumor growth. Subsequently, many SIRT2 selective inhibitors have been developed to target cancers. Among them, a mechanism-based SIRT2 inhibitor named TM is a lead compound with a potent antiproliferative effect. TM-induced SIRT2 inhibition had degraded oncoprotein c-Myc and effectively reduced breast cancer tumor growth. Nevertheless, TM possesses several limitations. Due to its long thiomyristoyl hydrophobic chain, TM has poor aqueous solubility, which makes the collection of the X-ray crystal structure of TM and SIRT2 challenging. Also, TM with poor aqueous solubility portrays limited bioavailability in cellular and animal studies. Another limitation of TM is that it can only inhibit SIRT2 deacetylase, not de-fatty acylase. Such simultaneous inhibition of both SIRT2 enzymatic activities could potentially increase the antiproliferative effect. In this thesis, several new SIRT2 selective inhibitors that have overcame these issues will be discussed. To improve the aqueous solubility, we have synthesized a glycoconjugated TM, named glucose-TM (Chapter Two). Even though glucose-TM had poor permeability, it had enabled us to collect X-ray co-crystal structure with SIRT2 and design additional inhibitors. To design a new SIRT2 modulator that inhibits both deacetylase and defatty-acylase, we have developed SIRT2 selective Proteolysis Targeting Chimera (PROTAC) inhibitor named TM-P4-Thal to degrade SIRT2 in cells (Chapter Three). For the accurate comparison of a pan SIRT1-3 inhibitor and a SIRT2 selective inhibitor, we synthesized NH4-6 and NH4-13 that have only one atom difference, but completely different sirtuin inhibition profile (Chapter Four). From the previous chapters, we have learned that both solubility and permeability are important for drug designs. To gain both characteristics, we have designed a simpler SIRT2 inhibitor with a benzodiazapienedione core, named NH-C1-10 (Chapter Five). NH-C1-10 inhibited SIRT2 slightly weaker than TM. However, in cellular studies, NH-C1-10 with improved bioavailability had shown stronger cytotoxicity and SIRT2 inhibition than TM.

Degree

thesis:*
Name thesis:degree_name
Ph. D., Chemistry and Chemical Biology
Level thesis:degree_level
Doctor of Philosophy
Discipline thesis:degree_discipline
Chemistry and Chemical Biology
Grantor
Cornell University
Year dc:date.issued
2021

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Hong, Jun Young
Chair dc:contributor.chair
  • Lin, Hening
Committee members dc:contributor.committeemember
  • Cerione, Richard A.
  • Schroeder, Frank

Subjects

dc:subject × 4

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Bibid
15160194
Dc Identifier Other
ProQuest Submission ID: 12706
ProQuest Publication ID: 28653014

Chain of custody

source
Harvested from
Cornell University
Base URL
ecommons.cornell.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Hong, Jun Young. DESIGN AND EVALUATION OF MECHANISM-BASED SIRT2 INHIBITORS WITH ENHANCED ANTICANCER POTENCY. Doctor of Philosophy thesis, Cornell University, 2021. https://hdl.handle.net/1813/110562